MigraineMind research summary
Chronic migraine management with onabotulinumtoxinA and anti-CGRP/R monoclonal antibodies in an Italian real-world setting: update on therapeutic appropriateness and an emerging role of pharmacy.
Front Pharmacol | 2026
Guideline / consensusSummary
Migraine is a challenging neurovascular disorder that can progress to chronic forms. This progression may result in medication-overuse headache, leading to higher healthcare costs. The need for preventive treatments has grown, including onabotulinumtoxin A and monoclonal antibodies. This study evaluated prescription patterns of these therapies in Italy. It compared data from 2023-2024 with previous years, specifically 2020-2022. The integration of pharmacists in migraine management has been noted. In 2023, there were 9,012 prescriptions, while 9,705 prescriptions were recorded in 2024. This shows an increasing trend in innovative preventive therapies. The use of eptinezumab and BoNT/A has gradually increased. This increase aligns with efforts to improve access to care and adherence to guidelines. However, therapeutic appropriateness has not yet reached the gold standard. Enhancing the role of pharmacists may lead to better clinical outcomes for patients. Clinical relevance: This study highlights the potential for pharmacists to enhance migraine management outcomes.
Key Learning Points
- Migraine can worsen over time, potentially leading to chronic headaches and increased healthcare costs.
- Preventive treatments like onabotulinumtoxin A and monoclonal antibodies are becoming more important in managing migraines.
- Prescription rates for innovative migraine therapies are on the rise, indicating improved access to care.
- The involvement of pharmacists in migraine management may improve treatment outcomes for patients.
- Current treatment practices have not yet achieved the highest standards of care for migraine patients.
Related migraine research topics
Original research
Read the original publication and review its full methods and findings on PubMed.
MigraineMind is an educational resource designed to complement—not replace—the original scientific literature or clinical judgement. This page is an AI-generated summary of the available paper information and may contain errors. Please consult the original publication.